Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (June 2021)

39 slides from Clearside Biomedical's investor presentation, Jun 15, 2021

  1. Slide 1: Corporate Presentation | June 2021

    Corporate Presentation | June 2021 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: Versatile Therapeutic Platform

    Versatile Therapeutic Platform SCS Microinjector® with proprietary drug formulations target the Suprachoroidal Space Proprietary Access to the Suprachoroidal Space (SCS®) Utilization Across Small Molecules and Gene Therapy Ability to Target Multiple Ocular Diseases Internal Research & Development Pi

  4. Slide 4: Core Advantages of Treating Via the Suprachoroidal Space

    Core Advantages of Treating Via the Suprachoroidal Space Sources: Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. | Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from poten

  5. Slide 5: Pioneers in the Suprachoroidal Space with Patented Technology

    Administration of any drug to the suprachoroidal space by microinjection Administration of any drug to the eye by inserting a microinjector into the sclera SCS Microinjector features Methods of using SCS Microinjector for drug delivery Device using an adjustable needle Pioneers in the Suprachoroidal

  6. Slide 6: Clearside's SCS Microinjector: The Only Clinically Tested Injection Device

    Clearside's SCS Microinjector®: The Only Clinically Tested Injection Device for Suprachoroidal Drug Delivery Clinically tested in >1200 suprachoroidal Injections 8 clinical trials completed Injections performed across multiple retinal disorders Safety profile comparable to intravitreal injections1 N

  7. Slide 7: Exclusive Access to the Back of the Eye Using Clearside's Proprietary SCS Microinjector

    Exclusive Access to the Back of the Eye Using Clearside’s Proprietary SCS Microinjector®

  8. Slide 8: CLS-AX Delivered with SCS Microinjector for Wet AMD

    CLS-AX Delivered with SCS Microinjector® for Wet AMD

  9. Slide 9: Suprachoroidal Space Injection Platform

    Suprachoroidal Space (SCS®) Injection Platform PARTNER THERAPEUTC ENTITY INDICATION IND-Enabling PHASE 2 PHASE 3 NDA REGENXBIO AAV-based Gene Therapy Wet AMD (AAVIATE) REGENXBIO AAV-based Gene Therapy Diabetic Retinopathy (ALTITUDE) AURA BIOSCIENCES Viral-like Drug Conjugate Ocular Oncology/Choroida

  10. Slide 10: XIPERE: Potential Suprachoroidal Approach to Treating Uveitic Macular Edema

    Macular edema is the leading cause of vision loss in patients with non-infectious uveitis NDA was resubmitted and accepted for review with PDUFA goal date of October 30, 2021 Commercialization and development partnerships to enhance value and expand patient access XIPERE™: Potential Suprachoroidal A

  11. Slide 11: Preclinical Data Supports Durability Potential of Small Molecule Suspensions

    Sources for in-vitro IC50 range: Stellato et al. J Allergy Clin Immol. 1999 volume 104, number 3, part 1 | Yuan et al. Haematologica 2017 Mar, 102(3) 466-475 | Inlyta, EMA 2012 May; CHMP assessment report | 2014 R13 HAE conference, Che, Wilson, Babu, Preclinical Characterization of BCX4161, an oral

  12. Slide 12: CLS-AX (axitinib injectable suspension) for Suprachoroidal Injection

    CLS-AX (axitinib injectable suspension) for Suprachoroidal Injection

  13. Slide 13: Age-Related Macular Degeneration (AMD)

    AMD causes a progressive loss of central vision and is the most common cause of blindness in individuals over age 55 Neovascular or Wet AMD accounts for the majority of blindness U.S. prevalence expected to increase to 22 million by the year 2050 Global prevalence expected to increase to 288 million

  14. Slide 14: Current Wet AMD Therapies Lead to Under-Treatment and Limited Real-World Outcomes

    Ceiling of efficacy Treatment burden Limited outcomes with current regimens CURRENT THERAPY On-label dosing involves fixed frequent injections With on-label anti-VEGF dosing, at 1 year1-3: ~1/5 of patients lose BCVA ~1/2 do not achieve ≥ 20/40 ~2/3 do not gain ≥ 3 lines BCVA In clinical trials, more

  15. Slide 15: CLS-AX for Suprachoroidal Injection in wet AMD

    CLS-AX (axitinib injectable suspension) for Suprachoroidal Injection in wet AMD Proprietary CLS-AX suspension formulation Potential to improve the treatment landscape for wet AMD patients Longer lasting treatment may reduce patient burden from monthly injections Targeted high levels to affected chor

  16. Slide 16: Axitinib: a Highly Potent, pan-VEGF TKI to Treat Wet AMD

    Axitinib: a Highly Potent, pan-VEGF TKI to Treat Wet AMD Axitinib’s intrinsic pan-VEGF inhibition through receptor blockade Approved treatments are focused VEGF-A inhibitors Inhibits VEGFR-1, VEGFR-2, VEGFR-3 receptors More effective than anti-VEGF-A in in-vitro angiogenesis model1-2 Highly potent t

  17. Slide 17: CLS-AX: High, Sustained Drug Levels in the Retina after SCS Administration

    Suprachoroidal Injection of CLS-AX Provides Targeted Delivery Relative to Intravitreal Injection at Same Dose 11x SCS vs IVT Retina / RPE-choroid-sclera 0.003X SCS vs IVT Vitreous humor Aqueous Humor SCS CLS-AX at or below level of detection Rabbit Model Values: area under the curve ratios, SCS / IV

  18. Slide 18: CLS-AX has Potential for Meaningful Durability

    CLS-AX has Potential for Meaningful Durability Therapeutic Levels > IC50 for 6 months after 1.05 mg/eye SC Injection in Rabbits Rabbit toxicology study with single bilateral suprachoroidal injection of axitinib, 1.05 mg/eye (n=4 eyes/ timepoint) On day 182, mean axitinib levels in the RPE-choroid-sc

  19. Slide 19: CLS-AX Has the Potential to Improve Current Wet AMD Treatment

    CLS-AX Has the Potential to Improve Current Wet AMD Treatment SCS Delivery May Synergistically Enhance Pan-VEGF Effect SAFETY EFFICACY TREATMENT BURDEN Well characterized small molecule Potential for less immune response & inflammation vs biological products Better compatibility with retinal pigment

  20. Slide 20: CLS-AX Phase 1/2a Clinical Trial in Wet AMD

    CLS-AX Phase 1/2a Clinical Trial in Wet AMD 2 mg aflibercept dosed at screening CLS-AX dosed at baseline (30 days post screening) Cohort Enrollment and Treatment Open-label study to evaluate safety and tolerability of escalating single doses of CLS-AX administered through suprachoroidal injection fo

  21. Slide 21: Cohort 1: Encouraging Results Support Progression to Cohort 2

    Cohort 1 Objective: To establish a floor of safety in this first-in-human trial with low dose CLS-AX (0.03 mg dose) Patients: Highly treatment-experienced Total number prior anti-VEGF treatments: mean = 25.8, median = 28.0 Total number prior anti-VEGF treatments within the last 12 months: mean = 9.0

  22. Slide 22: Cohort 1: Summary of Primary and Secondary Measures

    1-month visual acuity improvement of 1 line post CLS-AX vs no change for aflibercept, at this initial low dose Aflibercept: 1-month BCVA change -0.2 ETDRS letters (p=0.862*) CLS-AX 0.03 mg: 1-month BCVA change +4.7 ETDRS letters (p=0.029*) with 5/6 patients improving by 4 or more letters Mean CST st

  23. Slide 23: Best Corrected Visual Acuity One Month Response

    Best Corrected Visual Acuity One Month Response Following Aflibercept 2 mg vs CLS-AX 0.03 mg 1 Mo Change after Aflibercept : -0.2 letters, P=0.862* 1 Mo Change after CLS-AX : +4.7 letters, P=0.029* Source: Clearside data on file. |. *Post hoc, unadjusted

  24. Slide 24: Central Subfield Thickness Stable at One Month

    Central Subfield Thickness Mean CST Stable within 50 µm at One Month 1 Mo Change after Aflibercept (2 mg) 1 Mo Change after CLS-AX (0.03 mg) Source: Clearside data on file.

  25. Slide 25: Cohort 1: Preliminary Signs of Potential Durability at Low Dose

    No subjects required additional treatment at 1 month post CLS-AX 2 of 6 subjects did not require additional treatment for 3 months post CLS-AX Cohort 1: Preliminary Signs of Potential Durability at Low Dose in Highly Treatment Experienced and Dependent Patients Therapies for nAMD up to 6 Months Prio

  26. Slide 26: OASIS Cohort 1 Results Support Advancing to Cohort 2

    OASIS Cohort 1 Results Support Advancing to Cohort 2 SAFETY CLS-AX well tolerated No signs of inflammation, vitreous haze, IOP safety signals, vasculitis, or intravitreal dispersion of investigational product VISUAL ACUITY At 1 month, 5 of 6 patients had improved BCVA >4 letters (mean +4.7 letters)

  27. Slide 27: Cohorts 2 and 3 Continue to Escalate Single CLS-AX Dose

    With 3.3x and 10x dosing in cohorts 2 and 3 respectively: We expect progressively increased durability, based on our preclinical pharmacokinetic studies And potential for better visual acuity outcomes than anti-VEGFA based on pan-VEGF inhibition Preclinical pharmacokinetic studies show progressively

  28. Slide 28: Early-Stage Pipeline

    Early-Stage Pipeline

  29. Slide 29: SCS Injection Platform and Integrin Inhibition

    The Opportunity Beyond the VEGF pathway Novel target Early industry validation in DME and AMD Advantages of targeted suprachoroidal administration with potential for: Improved safety profile, through compartmentalization in SCS Enhanced efficacy, through drug levels at affected tissues Extended dura

  30. Slide 30: Integrin Small Molecule Suspension for SCS administration

    Integrin Small Molecule Suspension for SCS administration Note: This image of integrin avβ3 extracellular domains has been released for public use by its creator and original copyright holder: http://www.ebi.ac.uk/. Multi-functional cell-adhesion molecules, heterodimeric receptors with a and β subun

  31. Slide 31: Suprachoroidal Injection of Gene Therapy May Offer Potential for Safe and Efficient Delivery

    Strategic Priority: Seeking a clinical development partner to advance SCS delivery of current gene therapy assets Suprachoroidal Injection of Gene Therapy May Offer Potential for Safe and Efficient Delivery Sources: Clearside data on file. | Campochiaro, P. A. (2019). AAV8-vectored suprachoroidal ge

  32. Slide 32: Corporate Partnerships & Milestones

    Corporate Partnerships & Milestones

  33. Slide 33: Enabling SCS Delivery of AAV Gene Therapy for Retinal Disease

    Enabling SCS Delivery of AAV Gene Therapy for Retinal Disease The Opportunity: Gene Therapy Exclusive worldwide rights to our SCS Microinjector for delivery of adeno-associated virus (AAV)-based therapeutics to the suprachoroidal space to treat wet AMD, diabetic retinopathy and other conditions for

  34. Slide 34: REGENXBIO: Two Phase 2 Trials Using SCS Microinjector

    REGENXBIO: Two Phase 2 Trials Using SCS Microinjector® Two multi-center, open-label, randomized, controlled, dose-escalation studies evaluating the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 RGX-314 for Treatment of Wet Age-Related Macular Degeneration (wet AMD) Phase 2

  35. Slide 35: Aura Biosciences: Phase 2 Ocular Oncology trial using SCS Microinjector

    Aura Bioscience: Phase 2 Ocular Oncology trial using SCS Microinjector® The Opportunity: Ocular Oncology Worldwide licensing agreement for the use of our SCS Microinjector to deliver their proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choro

  36. Slide 36: XIPERE: Two Global Commercialization & Development Partners

    XIPERE: Two Global Commercialization & Development Partners XIPERE™ is an investigational product License for the U.S. and Canada; options for other territories Received $5M upfront payment Up to $15M in FDA approval and pre-launch milestones Up to $57.3M in milestone payments; tiered royalties from

  37. Slide 37: Four Validating Partnerships to Drive Growth

    1 2 3 4 Maximizes the commercial and development opportunities for XIPERE in multiple geographic markets Validates our investment in suprachoroidal delivery using our SCS Microinjector Expands our overall internal and collaborative product development pipeline Eligible to receive >$230M from the fou

  38. Slide 38: 2021 Research and Development Investment Highlights

    2021 Research and Development Investment Highlights *REGENXBIO (RGNX) trials involve suprachoroidal delivery of RGX-314 using the SCS Microinjector; Aura Biosciences trials involve suprachoroidal delivery of AU-011 using the SCS Microinjector; Arctic Vision program involves suprachoroidal delivery o

  39. Slide 39: Nasdaq: CLSD

    Nasdaq: CLSD

Clearside Biomedical — Investor Presentation (June 2021) on 6ix